The global Anti-Malarial Drugs Market is estimated to be valued at US$ 989.7 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Anti-malarial drugs are used for the prevention and treatment of malaria. Malaria is caused by protozoan parasites of the genus Plasmodium and is transmitted by the bites of infected Anopheles mosquitoes. The disease is common in tropical and subtropical regions, including parts of the Americas, Asia, and Africa. Anti-malarial drugs help reduce disease severity and prevent complications in high-risk groups.
Market key trends:
Growing adoption of telehealth is one of the key trends fueling the market growth. Evolving technology has enabled healthcare providers to deliver medical consultations and treatment virtually. Telehealth programs provide remote monitoring of malaria cases and increase access to diagnosis and treatment in remote areas. This helps reduce disease transmission and strengthens surveillance measures. Furthermore, increasing investments by governments and private organizations to develop novel anti-malarial drugs to fight drug resistance is also expected to support the market expansion over the forecast period.
Segment Analysis
The global anti-malarial drugs market is segmented based on drug class, distribution channel, and region. Based on drug class, the market is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, sulfadoxine, artemisinin and derivatives, and others. The artemisinin and derivatives segment dominates the market due to strong efficacy against malaria infections as well as WHO endorsing artemisinin-based combinations as the first-line treatment for P. falciparum malaria.
Key Takeaways
The global anti-malarial drugs market size is expected to reach US$ 1,377.2 million by 2030, expanding at a CAGR of 4.5% over the forecast period. Growing incidence of malaria infections worldwide due to factors such as climate change, trade globalization and ease of international travel is expected to drive the market.
Regional analysis
Regionally, the market is expected to witness higher growth in the Asia Pacific region over the forecast period. This growth can be attributed to presence of developing economies like India and Sri Lanka which have high malaria prevalence rates. Additionally, expanding healthcare infrastructure and growing awareness around malaria treatment and prevention in the region is also expected to support the market expansion.
Key players
Key players operating in the anti-malarial drugs market are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd. Major players are focused on developing new formulations with added efficacy as well as undertaking initiatives to increase access to anti-malarial drugs in endemic regions.
No comments:
Post a Comment